Italia markets close in 7 hours 8 minutes

FTSE MIB
34.631,95
-193,06(-0,55%)
Dow Jones
39.806,77
-196,82(-0,49%)
Nasdaq
16.794,88
+108,91(+0,65%)
Nikkei 225
38.946,93
-122,75(-0,31%)
Petrolio
79,16
-0,64(-0,80%)
Bitcoin EUR
65.317,27
+3.709,12(+6,02%)

NBIX May 2024 145.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

0,2500

+0,2000

(+400,00%)

In data: 01:39PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat